CLINICAL USE


Myasthenia gravis

DOSE IN NORMAL RENAL FUNCTION

0.3–1.2 g per day in divided doses

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :261.1
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data
  • %Excreted unchanged in urine &nbsp &nbsp : 80–90

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.8–1.4

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :3–4/6

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    20–30 35% of daily dose
  • 10 to 20 &nbsp &nbsp : 35% of daily dose
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 20% of daily dose

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL/min
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in GFR <10 mL/min
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAminoglycosides, clindamycin and polymyxins antagonise effects of pyridostigmine

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    Tags:

    • Related News

    ffddfd

    Hyperlipidemia